Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An Open-label, Randomized, Three-period, Crossover Study to Compare the Pharmacokinetics of GB1211 Upon Dosing a Capsule Under Fasting Condition and a Tablet Under Fasting and Fed Conditions in Healthy Volunteers

Next Previous
Trial Profile

An Open-label, Randomized, Three-period, Crossover Study to Compare the Pharmacokinetics of GB1211 Upon Dosing a Capsule Under Fasting Condition and a Tablet Under Fasting and Fed Conditions in Healthy Volunteers

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 21 May 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Selvigaltin (Primary)
  • Indications Liver cirrhosis; Non-small cell lung cancer
  • Focus First in man; Pharmacokinetics
  • Sponsors Galecto Biotech

Most Recent Events

  • 29 Mar 2024 Results assessing Pharmacokinetic Evaluation of Gb1211 in a Novel Tablet Formulation, Administered Under Fasted and Fed Conditions, and Compared to Gb1211 Capsules, in Healthy Volunteers presented at the 125th Annual Meeting of the American Society for Clinical Pharmacology and Therapeutics
  • 31 Aug 2023 Status changed from active, no longer recruiting to completed.
  • 04 May 2023 Planned End Date changed from 15 Apr 2023 to 30 Jun 2023.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top